PT2931291T - Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas - Google Patents

Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Info

Publication number
PT2931291T
PT2931291T PT138634449T PT13863444T PT2931291T PT 2931291 T PT2931291 T PT 2931291T PT 138634449 T PT138634449 T PT 138634449T PT 13863444 T PT13863444 T PT 13863444T PT 2931291 T PT2931291 T PT 2931291T
Authority
PT
Portugal
Prior art keywords
psychotherapy
adjunct
xenon
psychiatric disorders
argon treatment
Prior art date
Application number
PT138634449T
Other languages
English (en)
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of PT2931291T publication Critical patent/PT2931291T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/02—Goggles
    • A61F9/029—Additional functions or features, e.g. protection for other parts of the face such as ears, nose or mouth; Screen wipers or cleaning devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0883—Circuit type
    • A61M16/0891—Closed circuit, e.g. for anaesthesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/22—Carbon dioxide-absorbing devices ; Other means for removing carbon dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0291—Xenon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0612—Eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2250/00—Specially adapted for animals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT138634449T 2012-12-11 2013-12-10 Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas PT2931291T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261735700P 2012-12-11 2012-12-11
US201361815363P 2013-04-24 2013-04-24

Publications (1)

Publication Number Publication Date
PT2931291T true PT2931291T (pt) 2021-12-03

Family

ID=50934872

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138634449T PT2931291T (pt) 2012-12-11 2013-12-10 Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Country Status (4)

Country Link
US (2) US9737562B2 (pt)
EP (1) EP2931291B1 (pt)
PT (1) PT2931291T (pt)
WO (1) WO2014093277A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
GB201409085D0 (en) * 2014-05-21 2014-07-02 David Helene N Argon is a mu opioid receptor antagonist
JP6622822B2 (ja) * 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
AU2016354447A1 (en) * 2015-11-09 2018-04-26 The Mclean Hospital Corporation Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
US10369323B2 (en) * 2016-01-15 2019-08-06 Robert Mitchell JOSEPH Sonification of biometric data, state-songs generation, biological simulation modelling, and artificial intelligence
US20200054671A1 (en) * 2016-10-31 2020-02-20 Nobilis Therapeutics, Inc. Treatment of anxiety disorder and augmentation of anti-anxiety interventions by administration of noble gas containing mixtures
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US10695217B2 (en) * 2017-12-12 2020-06-30 Huseyin Yetik System to provide humidified controlled high pressure air during ocular surgery
RU2712804C1 (ru) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Способ коррекции функционального состояния человека в замкнутом пространстве
GB2615034A (en) * 2018-12-18 2023-07-26 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
CA3138008A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20230218570A1 (en) * 2020-06-17 2023-07-13 Lobe Sciences Ltd. Methods and Compositions for Treating Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder
EP4243811A1 (en) * 2020-07-21 2023-09-20 Neuritek Ltd. Uses of fatty acid amide hydrolase inhibitors in treatment of trauma related psychiatric disorders
JP2024514546A (ja) * 2021-04-02 2024-04-02 ナーゲル，ピーター 亜酸化窒素により治療抵抗性うつ病性障害を治療するための組成物及び方法
AU2022283967A1 (en) * 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
WO2023015154A1 (en) 2021-08-06 2023-02-09 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
WO2023191952A1 (en) * 2022-03-31 2023-10-05 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4354488A (en) 1980-11-24 1982-10-19 Dow Corning Corporation Nose mask gas delivery device
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
US4660555A (en) 1984-09-21 1987-04-28 Payton Hugh W Oxygen delivery and administration system
US4721060A (en) 1986-07-17 1988-01-26 Battelle Memorial Institute Nose-only exposure system
US4742824A (en) 1986-11-19 1988-05-10 Hugh W. Payton Oxygen tube support patch
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5243971A (en) 1990-05-21 1993-09-14 The University Of Sydney Nasal mask for CPAP having ballooning/moulding seal with wearer's nose and facial contours
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5348000A (en) 1993-07-19 1994-09-20 Teves Leonides Y Apparatus and method for dispensing oxygen and anesthesia via interchangeable facemask and nasal catheter
US5413095A (en) 1994-04-15 1995-05-09 Arrow Precision Products, Inc. Mouthpiece with oxygen receiving and directing structure
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
AUPO126596A0 (en) 1996-07-26 1996-08-22 Resmed Limited A nasal mask and mask cushion therefor
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6125844A (en) 1998-04-30 2000-10-03 Westwood Biomedical Portable oxygen based drug delivery system
US20040030639A1 (en) 2002-02-22 2004-02-12 Lendingtree, Inc. Method and computer network for co-ordinating a loan over the internet
ES2439274T3 (es) 1999-03-03 2014-01-22 Optinose As Dispositivo de administración nasal
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
US6595215B2 (en) 2000-03-13 2003-07-22 Innomed Technologies, Inc. Ventilation interface for sleep apnea therapy
US6247470B1 (en) 1999-07-07 2001-06-19 Armen G. Ketchedjian Oxygen delivery, oxygen detection, carbon dioxide monitoring (ODODAC) apparatus and method
FR2797770B1 (fr) 1999-08-30 2002-06-14 Air Liquide Equipement d'oxygenotherapie avec dispositif d'assistance respiratoire sans tube nasal
DE29916220U1 (de) 1999-09-15 2000-01-27 Transmit Technologietransfer Kombinationsmundstück für Inhalationstherapiegeräte sauerstoffabhängiger Patienten
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
IL158300A0 (en) 2001-04-27 2004-05-12 Bristol Myers Squibb Co Bisarylimidazol derivatives and pharmaceutical compositions containing the same
US6408853B1 (en) 2001-06-27 2002-06-25 Ti-Li Chang Medical facemask and a mold for manufacturing the medical facemask
AU2002359759B2 (en) 2001-12-21 2006-03-02 Exelis Inc. Video enhanced night vision goggle
AU2003210824A1 (en) 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
US7000611B2 (en) 2002-03-26 2006-02-21 Klemperer Walter G Mouthpiece, nasal seal, head appliance, apparatus, and methods of treating sleep apnea
CN1655849B (zh) 2002-05-22 2010-05-05 生物国际株式会社 鼻罩
WO2004010932A2 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US6807966B2 (en) 2002-08-21 2004-10-26 Medical Device Group, Inc. Oxygen delivery system and method of using same
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
US20050081849A1 (en) 2003-09-18 2005-04-21 Sydney Warren Personal oxygen and air delivery system
FR2863169B1 (fr) 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
US20050205098A1 (en) 2004-03-19 2005-09-22 Samsun Lampotang Apparatus and method to deliver dilute O2 by nasal cannula or facemask
US6981502B2 (en) 2004-04-01 2006-01-03 Numask, Inc. Respiratory mask having intraoral mouthpiece with large sealing area and multiple sealing configuration
US20060084659A1 (en) 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
RU51501U1 (ru) 2005-04-26 2006-02-27 Закрытое акционерное общество АТОМ-МЕД-ЦЕНТР Система терапии газовыми смесями как медикоментозная поддержка психотерапевтических процедур
US7866320B2 (en) 2005-06-08 2011-01-11 Nichols Heath C Nasal canula and mouthpiece assembly and method
TW200821296A (en) 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
FR2903654B1 (fr) 2006-07-13 2008-09-05 Spirotechnique Sa Dispositif d'alimentation en gaz respiratoire, notamment pour un embout buccal de plongeur
GB2440316A (en) 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
RU59415U1 (ru) 2006-08-28 2006-12-27 Сергей Александрович Наумов Устройство для ингаляции
US20090181953A1 (en) 2008-01-14 2009-07-16 Wyeth Compound forms and uses thereof
US9180191B2 (en) 2009-10-16 2015-11-10 University Of South Florida Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
US8313441B2 (en) 2010-03-11 2012-11-20 Dichonics Corporation Neuroaudiological central auditory test apparatus and method of differentiation of the neural correlates in PTSD, TBI, autism, ADHD, et al
EP2571360A4 (en) 2010-05-19 2013-07-31 Univ North Carolina METHODS AND FORMULATIONS FOR THE TREATMENT BY OXYTOCINE OF DISORDERS RELATED TO THE USE OF TOXIC SUBSTANCES, PSYCHIATRIC DISORDERS AND OTHER DISORDERS
FR2960778B1 (fr) 2010-06-03 2012-07-13 Air Liquide Medicament inhalable a base de xenon pour prevenir les rechutes addictives
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Also Published As

Publication number Publication date
US20150306136A1 (en) 2015-10-29
EP2931291A1 (en) 2015-10-21
US9737562B2 (en) 2017-08-22
WO2014093277A1 (en) 2014-06-19
EP2931291A4 (en) 2016-08-03
EP2931291B1 (en) 2021-10-20
US20170312308A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
EP2931291A4 (en) XENON AND / OR ARGONINE TREATMENT AS AN ADDITION TO PSYCHOTHERAPY IN PSYCHIATRICAL DISEASES
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HK1209745A1 (en) Compounds and methods for antiviral treatment
IL261659A (en) Brain cancer treatment
EP2906208A4 (en) THERAPEUTIC TREATMENT
LT3626270T (lt) Širdies ir kraujagyslių ligų gydymas
EP2922511A4 (en) TREATMENT DEVICE FOR EYELID
HRP20190038T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
IL239374B (en) Preparations and methods for treating brain tumors
HK1204573A1 (en) Treatment of inflammatory skin disorders
EP2903643A4 (en) TREATMENT OF PSYCHIATRIC DISEASES
GB201303721D0 (en) Compositions for treatment of sleep disorders
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment